Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX for Reduction of Masseter Muscle Prominence
2022-500568-37-00Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in masseter hypertrophy comparing BOTOX arm with Placebo arm (2 arms). Primary endpoints: MMPS ≥ 2-grade improvement (investigator) and MMPS-P ≥ 2-grade improvement (subject). Started Feb 2023; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
masseter hypertrophy
Beyond the preview
Go deeper on 2022-500568-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500568-37-00.